---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 20, 2004

 

---

 

AmerisourceBergen Corporation

(Exact name of Registrant as specified in its charter)

 

---

 

Delaware		1-16671		23-3079390
(State or Other Jurisdiction of Incorporation or Organization)		Commission File Number		(I.R.S. Employer Identification Number)

 

1300 Morris Drive Chesterbrook, PA		19087
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: (610) 727-7000

 

N/A

(Former name or former address, if changed since last report.)

 

---

---

Item 5. Other Events.

 

On January 20, 2004, AmerisourceBergen Corporation (the “Registrant”) issued a news release announcing that its wholly owned subsidiary, AmerisourceBergen Drug Corporation, will file a protest on January 21, 2004 in the United States Court of Federal Claims of the recent award by the Department of Veterans Affairs (VA) of its Pharmaceutical Prime Vendor contract commencing April 2004 to a competitor of the Registrant. A copy of the news release is filed as Exhibit 99.1 to this report and incorporated herein by reference.

 

Item 7. Financial Statements and Exhibits.

 

(c)

Exhibits.

 

99.1

News Release dated January 20, 2004

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		AMERISOURCEBERGEN CORPORATION
Date: January 20, 2004		By:		/s/ Michael D. DiCandilo
		Name:		Michael D. DiCandilo
		Title:		Senior Vice President and Chief Financial Officer